Search

Your search keyword '"Hirsch FR"' showing total 233 results

Search Constraints

Start Over You searched for: Author "Hirsch FR" Remove constraint Author: "Hirsch FR" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
233 results on '"Hirsch FR"'

Search Results

1. Loss of STING expression is prognostic in non-small cell lung cancer

2. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

Catalog

Books, media, physical & digital resources

4. TIM-3, a promising target for cancer immunotherapy

5. sLAG-3 in non-small-cell lung cancer patients’ serum

6. Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules

7. Clinical potential of necitumumab in non-small cell lung carcinoma

8. Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases

9. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

10. Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

11. The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016

12. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial

14. Calls to action on lung cancer management and research.

15. Lung cancer research and treatment: global perspectives and strategic calls to action.

16. Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).

17. Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations: Recommendations From the International Association for the Study of Lung Cancer Pathology Committee.

18. Extracellular vesicles containing SARS-CoV-2 proteins are associated with multi-organ dysfunction and worse outcomes in patients with severe COVID-19.

19. Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections.

20. Proceedings of the 1st biannual bridging the gaps in lung cancer conference.

21. RAC1 inhibition ameliorates IBSP-induced bone metastasis in lung adenocarcinoma.

22. New promises and challenges in the treatment of advanced non-small-cell lung cancer.

23. Rediscovering immunohistochemistry in lung cancer.

24. Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer.

25. The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast.

26. Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.

27. Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC.

28. Small cells - big issues: biological implications and preclinical advancements in small cell lung cancer.

29. Spatial transcriptomics reveals heterogeneity of histological subtypes between lepidic and acinar lung adenocarcinoma.

30. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer.

31. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.

32. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.

33. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT).

34. Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer.

35. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions.

36. Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsies.

37. Role of Lactate in the Regulation of Transcriptional Activity of Breast Cancer-Related Genes and Epithelial-to-Mesenchymal Transition Proteins: A Compassion of MCF7 and MDA-MB-231 Cancer Cell Lines.

38. Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?

39. Radiotherapy and Immunotherapy in Lung Cancer.

40. The presence of circulating genetically abnormal cells in blood predicts risk of lung cancer in individuals with indeterminate pulmonary nodules.

41. Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review.

42. Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer.

43. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.

44. Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment.

45. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee.

47. Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States.

48. Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).

49. Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization.

50. Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis.